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Endothelial dysfunction increases cardiovascular disease risk in chronic kidney disease (CKD). This study investigates whether
VDR activation aﬀects endothelial function in CKD. The 5/6 nephrectomized (NX) rats with experimental chronic renal
insuﬃciency were treated with or without paricalcitol, a VDR activator. Thoracic aortic rings were precontracted with
phenylephrine and then treated with acetylcholine or sodium nitroprusside. Uremia signiﬁcantly aﬀected aortic relaxation
(−50.0 ± 7.4% in NX rats versus −96.2 ± 5.3% in SHAM at 30μM acetylcholine). The endothelial-dependent relaxation was
improved to –58.2±6.0%, –77.5±7.3%, and –90.5±4.0% in NX rats treated with paricalcitol at 0.021, 0.042, and 0.083μg/kg for
two weeks, respectively, while paricalcitol at 0.042μg/kg did not aﬀect blood pressure and heart rate. Parathyroid hormone (PTH)
suppression alone did not improve endothelial function since cinacalcet suppressed PTH without aﬀecting endothelial-dependent
vasorelaxation. N-omega-nitro-L-arginine methyl ester completely abolished the eﬀect of paricalcitol on improving endothelial
function. These results demonstrate that VDR activation improves endothelial function in CKD.
1.Introduction
Chronic kidney disease (CKD) patients experience a high
mortality rate from cardiovascular (CV) diseases [1, 2].
Endothelial dysfunction—characterized by a disruption in
the delicate balance among vasodilation, oxidative stress,
inﬂammation, thrombosis, and ﬁbrinolysis maintained by
the endothelium—has been linked to increased cardiovas-
cular disease (CVD) risk [3–6]. Endothelial dysfunction
is commonly observed in CKD, likely preceding other
cardiovascular complications [7]. Not only do changes in
renal endothelial function aﬀect the progression of renal dis-
ease, but also systemic endothelial dysfunction signiﬁcantly
contributes to the severity of cardiovascular complications
in CKD. CKD patients usually have hypertension [8] and/or
diabetes [9], two of the conventional cardiovascular risk
factors that are associated with endothelial dysfunction.
In addition, likely other renal speciﬁc mechanisms may
contribute to endothelial dysfunction in CKD. In early CKD
one of the ﬁrst serum parameters to be altered is a decrease
in the serum 1,25-dihydroxyvitamin D3 levels [10], which
raises the question of whether deﬁcient VDR activation
may be one of the renal speciﬁc risk factors for endothelial
dysfunction in CKD. In addition, preclinical studies show
that VDR may be involved in modulating smooth muscle cell
proliferation/diﬀerentiation, the renin-angiotensin system,
inﬂammation, thrombosis, and ﬁbrinolysis; many of these
factors are involved in endothelial function [11, 12].
Vitamin D3 is made in the skin, but requires activa-
tion into the active hormone, 1,25-dihydroxyvitamin D3
(1α,25(OH)2D3, calcitriol), for its proper functions. Cal-
citriol exerts its functions via binding to a nuclear receptor,
the vitamin D receptor (VDR). Calcitriol and its analogs
such as paricalcitol (19-nor-1α,25(OH)2D2) that activate
vitamin D receptor (VDR) are commonly used to manage
hyperparathyroidism secondary to CKD [13]. Numerous2 International Journal of Endocrinology
clinical observations show that VDR activation therapy was
associated with a survival beneﬁt in CKD patients with an
eﬀectiveness order of: paricalcitol > calcitriol > no VDR
activation therapy, independent of the parathyroid hormone
(PTH) and calcium levels; the survival beneﬁt of VDR
activation agents is likely associated with a decrease in
cardiovascular-related mortality [14–18]. The mechanism(s)
of action for the cardiovascular and survival beneﬁt of VDR
activation agents in CKD is still not well understood.
VDR has been identiﬁed in more than 30 diﬀerent
tissues in the human body including the vasculature, and
emerging evidence suggests that VDR may play a role in
modulating cardiovascular functions [19]. Vitamin D and
vitamin D analogs that activate VDR (VDR agonists or
activators, VDRAs) have been shown to modulate inﬂam-
mation, thrombosis, and vasolidation, which are some
of the important risk factors associated with endothelial
dysfunction [20]. However, it is not well studied how VDRAs
aﬀect endothelial function in CKD. The 5/6 nephrectomized
(NX) uremic rat model is a useful model for studying renal
insuﬃciencyandhasbeenusedextensivelyfortheevaluation
of VDRAs on modulating serum calcium and PTH. Besides
havingelevatedPTH,the5/6uremicratsdevelopendothelial
dysfunction [21], left ventricular hypertrophy [22], and
proteinuria [23]. In this study, we employed paricalcitol to
investigatewhetherVDRactivationmitigatesthedetrimental
eﬀect of uremia on endothelial function in the 5/6 NX
rats. Our results demonstrate that uremia signiﬁcantly com-
promises endothelial function while paricalcitol improves
endothelial function in uremic rats in a dose-dependent
manner independent of serum PTH levels or blood pressure.
2. Methods
2.1. Materials. Paricalcitol (19-nor-1α, 25-dihydroxyvitamin
D2, 19-nor-1α, 25(OH)2D2), and cinacalcet (N-[1-(R)-
(−)-(1-naphthyl)ethyl]-3-[3-(triﬂuoromethyl)phenyl]-1-
aminopropane hydrochloride) were provided by Abbott
Laboratories. Other reagents were of analytical grade.
2.2. Subtotally Nephrectomized Rats. The investigation con-
forms with the Guide for the Care and Use of Laboratory
Animals published by the US National Institutes of Health
(NIH Publication No. 85-23, revised 1996), and all exper-
iments were approved by the Abbott Laboratories Internal
AnimalCareandUseCommittee.Male,Sprague-Dawleyrats
were obtained from Charles River. The nephrectomy was
performed on rats weighing ∼200g with a standard two-step
surgical ablation procedure [24]. Rats were maintained on
the Teklad 8640 diet containing 1.13% Calcium and 0.94%
Phosphorus. Elevated creatinine levels conﬁrmed uremia for
all 5/6 nephrectomized rats.
2.3. Vascular Function Studies. Rats of established uremia
were studied at Week 6 after surgery. In the paricalcitol stud-
ies, 5/6 nephrectomized rats received vehicle (5% EtOH/95%
propylene glycol; 0.4mL/kg; i.p.) or paricalcitol (doses as
indicated) 3x/wk over a period of 12 days (6 doses total),
and blood was drawn on Days 0 (24 hours before the ﬁrst
dose of treatment) and 13 (24 hours after the last dose
of treatment), and assayed for creatinine, BUN, PTH, total
calcium (Ca) and/or ionized Ca (iCa), and phosphorus (Pi).
Inthecinacalcetstudies,uremicratsweretreatedwithvehicle
(Cavitron, 1.65mL/kg; p.o) or cinacalcet (30mg/kg; p.o.)
daily for 13 days, and blood was drawn on days 0 and 13 (2
hours postdose) for testing. Untreated, age-matched SHAM
ratsservedascontrols.Insomestudies,untreateduremicrats
werecomparedwithvehicle-treateduremicratstoinvestigate
the eﬀect of vehicle. Rats were anesthetized with Nembutal
(100mg/kg). Thoracic aortas were excised, cut into sections
a n da na o r t i cr i n gs u s p e n d e di n1 0 m Lt i s s u eb a t h su n d e r
0.5 grams of resting tension in a modiﬁed Krebs solution
containing (in mmol/L) 120 NaCl, 20 NaHCO3,1 1d e x t r o s e ,
4.7 KCl, 2.5 CaCl2,1 . 5M g S O 4,a n d1 . 2K H 2PO4 equilibrated
with 5% CO2–95% O2 (pH 7.4 at 37
◦C). Tension was
recordedwithGrassFT03isometrictransducers(Astro-Med,
West Warwich, RI) connected to a Grass 7D polygraph
and a Ponemah data acquisition system (Data-Sciences
Intl, St. Paul, MN). Aortas were sensitized by addition of
phenylephrine(PE,3μM)with10-minutewashoutsbetween
intervals. Aortas were precontracted with PE (3μM), and
the endothelium-dependent vasodilator acetylcholine (ACh)
was added in half-log increments (1nM–30μM) at 3–
5 minute intervals, allowing time for the eﬀect of ACh
to plateau. After a 60-minute washout, aortas were pre-
contracted with PE (3μM) and subsequently treated with
endothelial-independent vasodilator sodium nitroprusside
(SNP; 1nM–1μM) at 3–5 minute intervals, allowing time
for the eﬀect to plateau. In a separate study, SHAM and 5/6
NX rats were treated with vehicle or paricalcitol at 0.16μg/kg
and aortic rings were preincubated with 100μM L-NAME
(N-omega-nitro-L-arginine methyl ester) for 1 hour prior to
the addition of PE to induce contraction. Due to the limited
availability of the tissue bath chambers, diﬀerent treatments
were independently given to diﬀerent groups of uremic rats
in order to properly prepare the aortic rings for relaxation
studies.
2.4. Measurement of PTH and Serum Mineral Levels. Serum
PTH was measured using a rat intact PTH ELISA kit
obtained from ALPCO/Immutopics, Inc. (Windham, NH).
SerumCa,Pi,creatinine,andBUNconcentrationsweremea-
sured using an Abbott Aeroset. Blood iCa was determined
using an i-STAT portable clinical analyzer with an EG7+
cartridge.
2.5. Measurement of Blood Pressure. In a separate study, male
Sprague-Dawley 5/6 nephrectomized rats at ∼4w e e k sa f t e r
nephrectomy were surgically implanted with transmitters.
Brieﬂy, animals were anesthetized with 3% isoﬂurane, and a
ﬂexible catheter attached to a TA11PA-C40 radio transmitter
(Data Sciences, St. Paul, MN ) was inserted in the abdominal
aorta just below the renal arteries, the procedure as recom-
mended by Data SciencesInternational [25]. The transmitter
was secured to the abdominal muscle and remained in the
abdominal cavity for the duration of the experiment. AfterInternational Journal of Endocrinology 3
surgery, rats were housed in individual cages positioned
over an RPC-1 radiotelemetry receiver (Data Sciences, St.
Paul, MN). Rats received food and water ad libitum.
Hemodynamic data were collected and summarized daily.
Rats were allowed to recover for 2 weeks postsurgery prior
to onset of dosing. Rats at 6 weeks after nephrectomy
were treated with vehicle (5% EtOH/95% propylene glycol;
0.4mL/kg; i.p.) or paricalcitol at 0.042μg/kg, 3x/week for 14
days. SHAM rats treated with vehicle were used as control.
One group of rats was given vehicle (i.p., 3x/week) plus
enalapril (10mg/kg, p.o., via drinking water, daily for 8 days,
then switched to 30mg/kg for another 6 days. The 30mg/kg
enalapril treatment did not further reduce blood pressure).
2.6. Data Analysis. For serum chemistry data, group mean ±
SEM are presented. Diﬀerences between SHAM and uremic
rats with diﬀerent treatments were assessed using a one-
way ANOVA followed by a Dunnett’s post-hoc test. A paired
t-test was used to assess diﬀerences between baseline Day
0 (before treatment) and Day 13 (after treatment) or as
indicated. For vascular function, ACh and SNP-induced
relaxations were calculated as the % of relaxation of the
PE-induced precontraction. Diﬀerences in vascular function
were determined using a two-way ANOVA, followed by a
Bonferonni post-hoc test.
3. Results
3.1. Eﬀect of Uremia and Paricalcitol Treatment on Endothelial
Function and Blood Chemistry. We examined the eﬀect of
uremia and paricalcitol treatment on acetylcholine-induced
endothelial-dependentrelaxationofaorticringsfromSHAM
and 5/6 NX rats. As shown in Figure 1(a), the maximal
aorta relaxation response to acetylcholine in SHAM rats
was −96.2 ± 5.3% with an EC50 of 137nM. Relaxation
was signiﬁcantly reduced in uremic 5/6 NX vehicle-treated
rats (−50.3 ± 7.0%, P< .01, with an EC50 of 211nM).
There was no diﬀerence in the relaxation response between
vehicle-treated and untreated uremic rats (data not shown).
The altered response to acetylcholine in the 5/6 NX rat
indicates compromised endothelial function. As shown
in Figure 1(b), the vascular relaxation produced by SNP
(endothelial-independent vasodilator) was not signiﬁcantly
diﬀerent between the SHAM and 5/6 NX rats, indicating that
the aorta vascular smooth muscle relaxant response is intact
and functional.
Figure 1(a) also shows that 2-week treatment with
paricalcitol produced dose-dependent improvement in
acetylcholine-induced endothelial-dependent relaxation.
Treatment with 0.083μg/kg of paricalcitol increased the
maximal relaxation response to acetylcholine to −90.5 ±
3.8% (P< .05) with an EC50 at 75nM. Treatment with
0.042μg/kg of paricalcitol shifted the EC50 to 121nM, and
increased the maximal relaxation response to acetylcholine
to −77.5 ± 6.9% (P< .05). To a lesser degree, treatment with
0.021μg/kg of paricalcitol increased the maximal relaxation
response to acetylcholine to −58.2 ± 6.0% with an EC50
at 105nM. Figure 1(b) shows that paricalcitol had no
signiﬁcant eﬀect on SNP-induced endothelial-independent
relaxation.
As shown in Figures 2(a) and 2(b), the serum crea-
tinine and BUN levels were signiﬁcantly elevated in the
5/6 nephrectomized (NX) rats compared to SHAM rats,
indicating a uniform disease state. Paricalcitol at the three
tested doses had no signiﬁcant eﬀect on either creatinine or
BUN (versus Day 0). Figure 2(c) shows that, as expected,
paricalcitol eﬀectively suppressed serum PTH in a dose-
dependent manner (a reduction of 41.6 ± 7.2%, 41.6 ± 7.4%
and 48.2 ± 8.3% at 0.021, 0.042 and 0.083μg/kg, resp.).
Total serum calcium (Ca), phosphorus (Pi), and ionized Ca
(iCa) levels were not signiﬁcantly diﬀerent in the 5/6 NX rats
versus SHAM. Paricalcitol signiﬁcantly increased serum Ca
and iCa at 0.042 and 0.083μg/kg (Figures 2(d) and 2(e)).
Paricalcitol at the three doses had no eﬀect on the Pi levels
(Figure 2(f)).
3.2. Paricalcitol Treatment Did Not Aﬀect Blood Pressure
and Heart Rate in 5/6 Nephrectomized Rats. To investigate
whether paricalcitol improves endothelial function via low-
ering blood pressure, we examined blood pressure and heart
rate in these animals. The angiotensin-converting enzyme
(ACE) inhibitor enalapril was used as a control. Mean
arterial pressure (MAP), systolic pressure (SP), and diastolic
pressure (DP) were elevated in 5/6 NX rats (Figures 3(a)–
3(c)). There was no signiﬁcant diﬀerence in heart rate
(Figure 3(d)). Enalapril exhibited a modest and stable eﬀect
on reducing mean arterial pressure, systolic pressure, and
diastolic pressure, but had no eﬀect on heart rate. As a
comparison, paricalcitol at 0.042μg/kg had no signiﬁcant
eﬀects on blood pressure or heart rate (Figure 3). Consistent
with the study in Figure 2, paricalcitol had no signiﬁcant
eﬀect on the creatinine, BUN, and serum Pi levels, while it
eﬀectively suppressed PTH and also signiﬁcantly increased
total serum Ca (data not shown). Enalapril did not show a
signiﬁcant eﬀect on the creatinine, BUN, PTH, serum Ca,
or Pi levels (data not shown). These results demonstrate
that paricalcitol at 0.042μg/kg did not aﬀect blood pressure,
suggesting that the eﬀect of paricalcitol at 0.042μg/kg on
improving endothelial function is independent of blood
pressure control.
3.3. PTH Suppression Alone Did Not Improve Endothelial
Function. To investigate whether serum PTH suppression
mediated by paricalcitol may have resulted in improved
endothelial function in the uremic rats, we took an indirect
approach and tested cinacalcet, a calcimimetic known to
suppress PTH via interacting with the calcium sensing
receptor independent of VDR. Consistent with the other
two studies (Figures 2 and 3), the serum creatinine and
BUN levels were elevated in the 5/6 NX rats compared
to SHAM rats, which were not signiﬁcantly aﬀected by
cinacalcet treatment at 30mg/kg for 13 days (data not
shown). Cinacalcet at 30mg/kg after 13 days of treatment
resulted in a decrease in serum PTH (a 66.8% reduction
versus before treatment, Figure 4(a))a n dt o t a ls e r u mC a
(a 23% reduction, Figure 4(b)). Cinacalcet signiﬁcantly4 International Journal of Endocrinology
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Figure 1: Endothelial dysfunction in 5/6 nephrectomized rats and the eﬀect of paricalcitol. SHAM and 5/6 NX rats were treated with
vehicle or paricalcitol at indicated doses as described in “Materials and Methods” (n = 9–11 per group). Aorta rings were precontracted
with phenylephrine (PE, 3μM), and the endothelium-dependent vasodilator acetylcholine was added in half-log increments (1nM–
30μM) at 3–5 minute intervals. Afterwards, aorta rings were precontracted with PE (3μM) and subsequently treated with endothelial-
independent vasodilator sodium nitroprusside (SNP, 1nM–1μM) at 3–5 minute intervals. (a) Acetylcholine-evoked relaxation. (b) SNP-
evoked relaxation.
elevatedserumphosphorusby18%(versusbeforetreatment;
data not shown). Figure 4(c) shows that the maximal aorta
relaxationresponsetoacetylcholineforthecinacalcet-treated
group was −41.8 ± 4.2% with an EC50 of 202nM, which
was not signiﬁcantly diﬀerent from the uremic 5/6 NX
vehicle-treated group. As shown in Figure 4(d), while there
was no signiﬁcant diﬀerence in SNP-induced endothelial-
independent relaxation between SHAM and uremic rats,
cinacalcet exhibited a modest eﬀect on reducing the vascular
relaxation produced by SNP. These results suggest that
PTH suppression is not linked to endothelial function
improvement in the uremic rats and the eﬀect of paricalcitol
on improving endothelial function may be independent of
PTH suppression.
3.4. L-NAME Abolished the Eﬀect of Paricalcitol on Improv-
ing Endothelial Function. To further investigate how VDR
activation improves endothelial function, we tested the
eﬀect of L-NAME. In this particular study, the maximal
aorta relaxation response to acetylcholine in SHAM rats
was −74.5 ± 3.6% with an EC50 of 157nM. Relaxation
was signiﬁcantly reduced in uremic 5/6 NX vehicle-treated
rats (−31.4 ± 4.7% with an EC50 of 358nM). As shown
in Figure 5(a), paricalcitol (0.16μg/kg, i.p., 3x/weeks for
two weeks) increased the maximal relaxation response to
acetylcholine to −52.3 ± 9.6% (P< .05) with an EC50 at
368nM. Addition of L-NAME at 100μM during the aorta
ring assay completely abolished the eﬀect of paricalcitol on
improving endothelial function. In this study, the serum
PTH level was signiﬁcantly reduced while the serum calcium
level was not altered by paricalcitol (Figures 5(b) and 5(c)).
4. Discussion
Previously it has been shown that, in spontaneously hyper-
tensive rats (SHR) with impaired endothelial function,
oral cholecalciferol (vitamin D3) treatment signiﬁcantly
improved the endothelium-dependent vascular relaxation
and hyperpolarization induced by acetylcholine [26]. Wong
et al. [27] have also shown that calcitriol acutely reduced
endothelium-dependent contractions in the aorta of the
spontaneously hypertensive rat. Karavalakis et al. [28]
reported that, in the 5/6 nephrectomized rats fed a special
diet that induced severe hyperphosphatemia, paricalcitol at
0.2μg/kg reduced vasoconstriction but increased calciﬁca-
tion in the large artery. As a comparison, our results show
that paricalcitol improves endothelial function in the 5/6 NX
rats with normal serum phosphate levels.
More importantly, our data demonstrate that paricalcitol
does not aﬀect blood pressure in the uremic rats during
the treatment period, suggesting that the eﬀect of parical-
citol on improving endothelial function is independent of
blood pressure control. Our observation is consistent with
the ﬁnding made by Bodyak et al. [29] that paricalcitol
attenuated the development of left ventricular abnormalities
in the Dahl salt-sensitive rat (a diﬀerent experimental
model from the 5/6 nephrectomized uremic rats) without a
signiﬁcant eﬀect on blood pressure. Karavalakis et al. [28]International Journal of Endocrinology 5
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Figure 2: The blood chemistry in 5/6 NX uremic rats before and after paricalcitol treatment. The experimental conditions were as described
in Figure 1. On Days 0 and 13 (24 hours after the last drug treatment), blood samples were collected for the measurement of (a) serum
creatinine, (b) BUN, (c) serum PTH, (d) serum Ca, (e) ionized Ca, and (f) serum Pi. Mean ± standard error was calculated for each group
(n = 9–11). One way ANOVA Dunnett test with 95% conﬁdence intervals of diﬀerence was performed for statistical comparisons (Figures
2(a) and 2(b)).6 International Journal of Endocrinology
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Figure 3:Eﬀectsofparicalcitolandenalaprilonbloodpressureandheartratein5/6NXrats.SHAMor5/6NXratsweretreatedwithvehicle
or paricalcitol at 0.042μg/kg as described in “Materials and Methods” (n = 8–10 per group). SHAM rats treated with vehicle were used as
control. One group of rats was given enalapril as another control. The arrow sign (Day 0) indicates the initiation of treatment. (a) Mean
arterial pressure (MAP), (b) systolic pressure (SP), (c) diastolic pressure (DP), and (d) heart rate. MAP was 156.5 ± 7.8mmHg in the 5/6
NX rat at Week 7 after surgery (i.e., Day 6 as shown in the graph) versus 107.1 ± 2.0mmHg in SHAM; SP was 181.0 ± 10.0 versus 127.8 ±
3.8mmHg; DP was 135.2 ± 6.6 versus 92.2 ± 1.5mmHg.
have also reported that, in the 5/6 nephrectomized rats
fed a special diet that induced severe hyperphosphatemia,
paricalcitol at 0.2μg/kg did not aﬀect blood pressure. In a
study reported by Mizobuchi et al. [23], 5/6 nephrectomized
uremic rats developed signiﬁcant hypertension, which was
not aﬀected by paricalcitol (0.8μg/kg) during a 4-month
treatment period, while enalapril eﬀectively lowered blood
pressure. However, it is worth mentioning that, in the study
by Freundlich et al. [30], the systemic blood pressure, which
increased in all groups with renal ablation (versus SHAM
rats), was signiﬁcantly lower in rats treated with paricalcitol
at either 0.1 or 0.3μg/kg. At this point it is not known
why the results were diﬀerent from diﬀerent laboratories
on a seemly similar uremic rat model. Hypertension is
closely linked to endothelial dysfunction [8]. Many drugs
that improve endothelial function also control hypertension,
making it diﬃcult to delineate the eﬀects of these drugs on
these two parameters. Like CKD patients, the 5/6 NX rats
have severe hypertension and endothelial dysfunction. The
observation from this study implies that it is possible to
improve endothelial function in CKD independent of blood
pressure control.
In this study, due to the short duration of the treatment
(2 weeks), paricalcitol didnot show an eﬀect on serum
creatinine and BUN. A study by Freundlich et al. [30]
reported that the plasma creatinine level, elevated in all
groups with renal ablation, started to decline after two
weeks of paricalcitol (0.1 and 0.3μg/kg) treatment in the
5/6 nephrectomized uremic rats, eventually reaching levels
comparable to SHAM rats and signiﬁcantly lower thanInternational Journal of Endocrinology 7
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Figure 4: Cinacalcet suppressed PTH, but did not improve endothelial dysfunction in 5/6 nephrectomized rats. SHAM and 5/6 NX rats
were treated with vehicle or cinacalcet as described in “Materials and Methods” (n = 8 per group). On Days 0 and 13 (2 hours after the drug
treatment),bloodsampleswerecollectedforbloodchemistryandPTH.Aorticringswereprecontractedwithphenylephrine(PE,3μM),and
the endothelium-dependent vasodilator acetylcholine was added in half-log increments (1nM–30μM) at 3–5 minute intervals. Afterwards,
aortic rings were precontracted with PE (3μM) and subsequently treated with endothelial-independent vasodilator sodium nitroprusside
(SNP, 1nM–1μM) at 3–5 minute intervals. (a) Serum PTH. (b) Serum Ca. (c) Acetylcholine-evoked relaxation. (d) SNP-evoked relaxation.
in nontreated 5/6 NX rats. Previously it has been shown
[23] that, during a 4-month treatment period following
nephrectomy, the increase in serum creatinine was less in
the paricalcitol (0.8μg/kg) group than in the untreated
group, although the diﬀerence failed to reach a statistical
signiﬁcance.
Elevated PTH has been shown to play a role in various
cardiovascular disorders including abnormal vasodilation
[31]. Previously it has also been demonstrated that, in
patients with primary hyperparathyroidism, parathyroidec-
tomy signiﬁcantly improved endothelial vasodilatory func-
tion [32]. The current study shows that PTH suppression
is not linked to endothelial function improvement in
the uremia rat since cinacalcet, a calcimimetic, does not
show a signiﬁcant eﬀect on improving endothelial function
although it suppresses PTH eﬀectively. These data are of
interest as they are consistent with the clinical observations
that the survival beneﬁt of VDR activation therapy in
hemodialysispatientsisobservedacrossdiﬀerentserumPTH
levels [14, 15].
We noticed the inconsistent eﬀects of paricalcitol on
aortic relaxation from study to study as evident in Figures
1 and 5. Paricalcitol at 0.083μg/kg in Figure 1 study almost
normalized endothelial function to the SHAM level, while8 International Journal of Endocrinology
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Figure 5: L-NAME abolished the eﬀect of paricalcitol on improving endothelial dysfunction in 5/6 nephrectomized rats. SHAM and 5/6
NX rats were treated with vehicle or paricalcitol at 0.16μg/kg as described in “Materials and Methods” (n = 9–11 per group). Aortic rings
were preincubated with 100μM L-NAME for 1 hour prior to the addition of PE to induce contraction, and the endothelium-dependent
vasodilator acetylcholine was added in half-log increments (1nM–30μM) at 3–5 minute intervals. (a) Acetylcholine-evoked relaxation. (b)
Serum PTH. (c) Serum Ca.
paricalcitol at 0.16μg/kg in Figure 5 study only partially
improved endothelial function. A few possibilities exist for
this discrepancy. Paricalcitol at a higher dose may decrease
localactivityofcalcitriolorparicalcitolviaCYP24induction.
Paricalcitol at the higher dose can also increase vascular
calciﬁcation, which leads to reduced aortic relaxation. Alter-
natively, it may be the result of the inconsistent eﬀects of
paricalcitol on serum calcium in diﬀerent batches of 5/6
nephrectomized uremic rats. It is of interest to note that
changes in the serum calcium levels may aﬀect endothelial
function. Calcium is required for the activity of nitric oxide
synthase, and thus, increasing extracellular or intracellular
calcium concentrations may stimulate nitric oxide (NO)
production. An increase in serum calcium may also alter the
intracellular calcium level, leading to opening of endothelial
calcium-sensitive potassium channels (K(+) channels) and
vessel relaxation. Jolma et al. [33] reported that high-
calcium diet enhanced resistance artery relaxation in the
5/6 NX rats likely mediated by K(+) channels. This eﬀect
was independent of the degree of renal impairment and
blood pressure, but was associated with improved calcium
metabolism because plasma levels of PTH and phosphate
were decreased and serum calcium was increased. At the
dose range of 0.021–0.16μg/kg that was used in this study,
paricalcitol sometimes raises serum calcium; the eﬀects vary
from studies to studies and the causes for this variation
is not well understood. For example, Noonan et al. [34]
have shown that paricalcitol at 0.083 and 0.167μg/kg raised
serum calcium levels while Wu-Wong et al. [35]r e p o r t e d
that paricalcitol at 0.17μg/kg did not aﬀect serum calciumInternational Journal of Endocrinology 9
levels.AsshowninFigures1and2,paricalcitolat0.083μg/kg
raisedserumcalciumandcompletelynormalizedendothelial
function to the SHAM level. As a comparison, paricalcitol
at 0.167μg/kg (Figure 5) did not raise serum calcium and
only partially normalized endothelial function. Consistent
with this notion, since serum calcium was signiﬁcantly lower
in the cinacalcet study (Figure 4), we cannot rule out the
possibility that the lack of eﬀect of cinacalcet on endothelial
function may be due to the decrease in serum calcium levels
after cinacalcet treatment.
Borges et al. [26] have shown that, in the SHR rat model,
cholecalciferol improved endothelial function likely medi-
ated by endothelium-derived hyperpolarizing factor, but not
nitricoxide.However,mountingevidencehasshownthatthe
systemic NO deﬁciency is the principal cause for endothelial
d y s f u n c t i o ni nC K D[ 36]. In a clinical study on hemodialysis
patients, Passauer et al. [37] reported that endothelial dys-
function in uremic patients as determined by endothelium-
dependent vasodilation in response to increased doses of
acetylcholine is mainly attributed to reduced NO activity.
Yamamizu et al. [38] have also reported that the decrease
of NO production was the key factor linked to endothelial
dysfunction in the 5/6 NX rats. Our data support the role of
NO in CKD that L-NAME completely abolished the eﬀect
of paricalcitol on improving endothelial function in the
uremic rats. The results suggest that paricalcitol treatment
restores the systemic NO activity in the 5/6 uremic rats.
Beside decreased nitric oxide generation, the accumulation
of asymmetric dimethylarginine (ADMA, an endogenous
nitric oxide inhibitor) is also known to contribute to
endothelial dysfunction. We did a search but did not ﬁnd any
published work on VDR activation and ADMA. Although
it is beyond the scope of this study, preliminary data from
employing DNA microarray technology to analyze the aortic
geneexpressionproﬁlinginthe5/6NXratsshowthaturemia
is associated with abnormal expression of genes involved
in increasing oxidative stress and paricalcitol treatment
normalizes many of these genes [39]. Very little is known
about VDR and oxidative stress. We hope the observations
made in this study will stimulate others to investigate further
about the role of VDR in regulating NOS, ADMA, and other
factors involved in oxidative stress.
In summary, VDR activation by paricalcitol signiﬁcantly
improves endothelial function in the 5/6 NX uremic rats.
More importantly, the eﬀect of paricalcitol is independent
of blood pressure control and the serum PTH levels.
Although randomized clinical studies are needed to conﬁrm
the cardiovascular and survival beneﬁt of VDR activation
therapy in CKD patients, data from the current study
provide an important new insight that VDR activation
improves endothelial function in uremia, which may be one
of the mechanisms responsible for the cardiovascular beneﬁt
associated with these drugs in CKD.
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